NORRISTOWN, Pa., December 17, 2021--(BUSINESS WIRE)--Thubrikar Aortic Valve, Inc., announced today that it received approval from a Competent Authority in Poland to conduct initial patient implants with its Optimum Transcatheter Aortic Valve Implantation (TAVI) systemâ„¢. The Company will sponsor this CE Mark-enabling pilot study on patients with severe Aortic Stenosis and begin to implant the first five patients in early 2022.
Optimum TAV™ is the shortest profile valve among self-expanding TAVs, and its short profile facilitates coronary access. The Company has designed a 2nd-generation delivery catheter - the Precision 2™ Catheter - making Optimum TAV repositionable, recapturable, and retrievable during the TAVI procedure. Optimum TAV’s short frame reorients as it is deployed in the diseased valve which results in axial alignment of the valve. The Precision 2™ Catheter, with its repositionability, provides good control during valve deployment and axial alignment.
Additionally, the Optimum TAV demonstrated the equivalent of over 24 years’ durability in bench testing, and showed less calcification than even surgical valves in extended animal implants. With the next-generation delivery catheter and enhanced valve durability, the Optimum TAVI system will be the system of choice for aortic valve replacement, particularly for younger patients. The first patient implanted with Optimum TAV continues to do well at three years.
Dr. Mano Thubrikar, inventor of the Optimum TAV and the Company’s Founder and President, stated, "We are thankful to our Engineers and Medical Advisors for this progress. Durability remains the key issue in TAVI - younger patients still require open-heart surgery because no approved TAVs have demonstrated the durability of surgical valves. We designed the Optimum TAV after the natural aortic valve because we discovered that it has the optimal geometry for efficient performance and durability. We also ensured that Optimum TAV’s leaflets do not contain suture holes. As a result, Optimum TAV has unparalleled durability and will greatly benefit patients."
Dr. Susheel Kodali, Director of the Structural Heart & Valve Center at New York-Presbyterian/Columbia University Medical Center, and Dr. Mathew Williams, Director of the Heart Valve Center at NYU Langone Health in the U.S., have been important advisors for the Company and have helped inspire the changes to the delivery catheter. They will continue to support the Company in its clinical trials.
Dr. Kodali is a recognized authority on percutaneous heart valves and his center was the lead investigational site for several of the large clinical trials that led to the approval of TAVI in the U.S. He has been an investigator for such clinical trials since 2007.
Dr. Williams is a widely recognized pioneer in transcatheter valve replacement and has conducted nearly 4,000 such procedures. He was the Lead Principal Investigator in the premarketing trials of self-expanding TAVs.
About Thubrikar Aortic Valve and Its Optimum TAVI Systemâ„¢
Thubrikar Aortic Valve, Inc. is a privately held medical device company based in Norristown, PA, that has developed a next-generation transcatheter aortic valve, the Optimum TAV, and delivery catheter, collectively called the "Optimum TAVI System." Optimum TAV was designed after the natural aortic valve using 30 years of research by the Company’s Founder, Dr. Mano Thubrikar. He served as Director of Surgical Research at the University of Virginia, Director of Biomedical Engineering at the Heineman Medical Research Foundation in Charlotte, Distinguished Research Scientist at Edwards Lifesciences, and Director of Biomedical Engineering at the South Dakota School of Mines and Technology. He is the author of "The Aortic Valve," a leading textbook covering the fundamentals of valve structure and function. For more information, please visit: www.tavi.us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216006162/en/
Thubrikar Aortic Valve Samir Wadke, Vice President of Business Development 610-630-8284 Samir.Wadke@tavi.us
KENILWORTH, N.J. & TOKYO, December 27, 2021--KEYTRUDA Plus LENVIMA Approved in Japan for Patients With Unresectable Advanced or Recurrent Endometrial Carcinoma That Progressed After Chemotherapy
Hundreds of Chinese companies are listed on U.S. markets. But which are the best Chinese stocks to buy or watch right now? JD.com , Nio, Li Auto, Xpeng and BYD Co.. China is the world's most-populous nation and the second-largest economy with a booming urban middle class and amazing entrepreneurial activity.
It’s a quiet day ahead on the economic calendar, with stats limited to French employment figures. The lack of stats will leave COVID-19 news in focus.
SPACs and venture capitalists are plowing money into startups at record rates, looking past worries about lofty valuations.
Will SPY continue the bull run in 2022 after the FED announced it will accelerate the reduction of its monthly bond purchases?
The Omicron strain weighed on mortgage rates going into the holidays. Rates are expected to rise, however, along side rising house prices to test demand.
Bitcoin and ether regained price levels from Friday after seeing a slight dip over an otherwise quiet Christmas weekend.
Appoints Sagar Ahuja as Director and to the Board with the additional responsibility to lead QX Accounting Services as CEO
SHANGHAI (Reuters) -The Chinese government will require that domestic firms in sectors off-limits to foreign direct investment, such as Internet news and publishing, receive clearances from regulators before they can list their shares outside the mainland. The National Development and Reform Commission (NDRC) announced the new rules on the clearances on Monday in a statement that also included an updated annual "Foreign Investment Negative List" that outlines business sectors where foreign direct investment is banned or restricted. The new rules now apply that list to companies issuing shares overseas for the first time, and come as China is tightening scrutiny over offshore share sales.
Baidu Inc (NASDAQ: BIDU) CEO Robin Li said Jidu Auto would mass-produce its first "robot" electric vehicle in 2023. Jidu is an electric vehicle venture between China's tech giant Baidu and Chinese automaker Geely Automobile Holdings Ltd (OTC: GELYY). Jidu looks to make EVs of the autonomous Level-four, which needs no human intervention, Li said at Baidu's annual developers' conference. Related Content: Baidu-Geely Joint Venture Aims .7B Investment In Smart Car, Baidu Hires CEO For EV Venture, Pl
Shares of Moderna Inc. were down 2.4% in trading on Monday after the company said Switzerland exercised an option to buy an additional seven million doses of its COVID-19 booster. Moderna said delivery of those shots is set to occur in the second half of 2022. Switzerland has ordered a total of 27.5 million doses from Moderna. The company's stock is up 134.1% this year, while the broader S&P 500 has gained 25.8%.
Stocks are hitting records as the variant surges. Why investors have brushed off the new wave of Covid.
The CEO of Connecticut-based Bridgewater Chocolate told Yahoo Finance that price and supply pressures haven't hit the company "yet."
'Rich Dad Poor Dad' is as bearish as ever.
If you want to build momentum for your New Year’s money resolutions, set some financial improvements into motion before the end of the year.
Bitcoin’s price rose by more than 70% in 2021 despite the bearish sentiment in China, and more gains are expected over the coming year.
Trading was light across different crypto exchanges on Christmas day and Boxing Day in the U.K.; ether’s price was roughly flat.
DiDi Global Inc (NYSE: DIDI) has prohibited current and former employees from selling company shares indefinitely, Financial Times reports. DiDi extended the prohibition from December 27 without setting a new end date. DiDi lost 60% of its value, or ~$38 billion in stock market capitalization, since its $4.4 billion U.S. initial public offering in June. Related Content: China's Latest Ride-Hailing Regulations Likely To Spell Trouble For DiDi, Alibaba Chinese authorities launched an investigation
As traders return from last week's holiday-shortened week, the price action heading into the new year will be closely monitored, especially given the relatively light economic data and earnings calendar for the coming days.
Shares of Alibaba Group Holding Ltd. rose 0.8% in morning trading Monday, after China's securities regulator's draft rules on overseas listings released over the long weekend OK'd the listing structure known as variable-interest entity (VIE) used by the e-commerce giant to list its shares on the NYSE. Alibaba's stock has now rallied 6.8% since closing at a 4 1/2-year low of $111.96 on Dec. 3, but was still down 20.4% over the past three months, and 48.6% year to date, while the S&P 500 has gaine